| Bioactivity | Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), MCF7 (IC50 = 0.55 μM, breast adenocarcinoma), respectively[1]. |
| Formula | C59H72ClF3N6O5S2 |
| Molar Mass | 1101.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Niels V Heise, et al. Dehydroabietylamine-substituted trifluorobenzene sulfonamide rhodamine B hybrids as anticancer agents overcoming drug resistance. Eur J Med Chem. 2024 Jul 10:276:116667. |
Anticancer agent 242
CAS: F: C59H72ClF3N6O5S2 W: 1101.82
Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC5
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.